4basebio AG announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was EUR 796,000 compared to EUR 896,000 a year ago. Operating loss was EUR 3.390 million compared to EUR 2.614 million a year ago. Net income was EUR 62.590 million compared to net loss of EUR 1.990 million a year ago. Basic earnings per share from continuing operations was EUR 1.22 compared to basic loss per share from continuing operations of EUR 0.04 a year ago. Diluted earnings per share from continuing operations was EUR 1.16 compared to diluted loss per share from continuing operations of EUR 0.03 a year ago.